Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03980184 · ClinicalTrials.gov registry record · Phase 2
Guanfacine to Improve Substance Use Outcomes in Women
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT03980184 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 74 participants.
The verdict
NCT03980184, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
Hypothesis: Guanfacine (GUA) (3mg/day) will reduce drug craving, improve cognitive flexibility and result in associated lower drug use in women with substance use disorder (SUD) in an outpatient clinical setting.
Interventions
- DRUG Guanfacine
- OTHER Behavioral Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2022-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03980184
The ClinicalTrials.gov registry entry for NCT03980184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Guanfacine is the first listed.
NCT03980184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03980184 about?
NCT03980184 is a clinical study titled "Guanfacine to Improve Substance Use Outcomes in Women". Hypothesis: Guanfacine (GUA) (3mg/day) will reduce drug craving, improve cognitive flexibility and result in associated lower drug use in women with substance use disorder (SUD) in an outpatient clinical setting.
What is the current status of trial NCT03980184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2019-11-01. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT03980184?
The interventions under investigation include: Guanfacine (DRUG), Behavioral Counseling (OTHER).
Who is sponsoring clinical trial NCT03980184?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.